Tero Aittokallio (T Aittokallio)

ResearcherID Scopus Author ID Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 63

Top Venues

PLoS computational biology

Nature communications

Bioinformatics (Oxford, England)

Leukemia

Oslo University Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Oslo University Hospital Sep 01 2019

Norway

Group Leader :: Institute for Cancer Research

University of Oslo Sep 01 2019

Norway

Professor :: Oslo Centre for Biostatistics and Epidemiology (OCBE)

University of Helsinki

Finland

FIMM-EMBL Group Leader :: Institute for Molecular Medicine Finland

Publications

Daria R Bulanova, Yevhen Akimov, Wojciech Senkowski, Jaana Oikkonen, Laura Gall-Mas, Sanna Timonen, Manar Elmadani, Johanna Hynninen, Sampsa Hautaniemi, Tero Aittokallio, Krister Wennerberg
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science advances 10 (21) (2024)
Aron Schulman, Juho Rousu, Tero Aittokallio, Ziaurrehman Tanoli
Attention-based approach to predict drug-target interactions across seven target superfamilies. Bioinformatics (Oxford, England) 40 (8) (2024)
Kristen Nader, Misra Tasci, Aleksandr Ianevski, Andrew Erickson, Emmy W Verschuren, Tero Aittokallio, Mitro Miihkinen
ScType enables fast and accurate cell type identification from spatial transcriptomics data. Bioinformatics (Oxford, England) 40 (7) (2024)
Kristen Nader, Misra Tasci, Aleksandr Ianevski, Andrew Erickson, Emmy W Verschuren, Tero Aittokallio, Mitro Miihkinen
ScType enables fast and accurate cell type identification from spatial transcriptomics data. Bioinformatics (Oxford, England) 40 (7) (2024)
Zhi Zhao, John Zobolas, Manuela Zucknick, Tero Aittokallio
Tutorial on survival modeling with applications to omics data. Bioinformatics (Oxford, England) 40 (3) (2024)
Zhi Zhao, John Zobolas, Manuela Zucknick, Tero Aittokallio
Tutorial on survival modeling with applications to omics data. Bioinformatics (Oxford, England) 40 (3) (2024)
Daria R Bulanova, Yevhen Akimov, Wojciech Senkowski, Jaana Oikkonen, Laura Gall-Mas, Sanna Timonen, Manar Elmadani, Johanna Hynninen, Sampsa Hautaniemi, Tero Aittokallio, Krister Wennerberg
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science advances 10 (21) (2024)
Aron Schulman, Juho Rousu, Tero Aittokallio, Ziaurrehman Tanoli
Attention-based approach to predict drug-target interactions across seven target superfamilies. Bioinformatics (Oxford, England) 40 (8) (2024)
Aleksandr Ianevski, Aleksandr Kushnir, Kristen Nader, Mitro Miihkinen, Henri Xhaard, Tero Aittokallio, Ziaurrehman Tanoli
RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies. Briefings in bioinformatics 25 (4) (2024)
Aleksandr Ianevski, Aleksandr Kushnir, Kristen Nader, Mitro Miihkinen, Henri Xhaard, Tero Aittokallio, Ziaurrehman Tanoli
RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies. Briefings in bioinformatics 25 (4) (2024)
Daria R Bulanova, Yevhen Akimov, Wojciech Senkowski, Jaana Oikkonen, Laura Gall-Mas, Sanna Timonen, Manar Elmadani, Johanna Hynninen, Sampsa Hautaniemi, Tero Aittokallio, Krister Wennerberg
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science advances 10 (21) (2024)
Jana von Jan, Sanna Timonen, Till Braun, Qu Jiang, Aleksandr Ianevski, Yayi Peng, Kathleen McConnell, Paola Sindaco, Tony Andreas Müller, Sabine Pützer, Hanna Klepzig, Dennis Jungherz, Annika Dechow, Linus Wahnschaffe, Anil K Giri, Matti Kankainen, Heikki Kuusanmäki, Heidi A Neubauer, Richard H Moriggl, Paolo Mazzeo, Nicole Schmidt, Raphael Koch, Michael J Hallek, Amel Chebel, David Armisen, Laurent Genestier, Emmanuel Bachy, Anjali Mishra, Alexandra Schrader, Tero Aittokallio, Mohamed El Missiry, Marco Herling
Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses. Blood (2024)
Anni S Halkola, Kaisa Joki, Tuomas Mirtti, Marko M Mäkelä, Tero Aittokallio, Teemu Daniel Laajala
OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer. PLoS computational biology 19 (3) (2023)
Anni S Halkola, Kaisa Joki, Tuomas Mirtti, Marko M Mäkelä, Tero Aittokallio, Teemu Daniel Laajala
OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer. PLoS computational biology 19 (3) (2023)
Anni S Halkola, Kaisa Joki, Tuomas Mirtti, Marko M Mäkelä, Tero Aittokallio, Teemu Daniel Laajala
OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer. PLoS computational biology 19 (3) (2023)
Moritz Otte, Johanna Stachelscheid, Markus Glaß, Linus Wahnschaffe, Qu Jiang, Waseem Lone, Aleksandr Ianevski, Tero Aittokallio, Javeed Iqbal, Michael Hallek, Stefan Hüttelmaier, Alexandra Schrader, Till Braun, Marco Herling
The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL. Cancers 15 (9) (2023)
Swapnil Potdar, Filipp Ianevski, Aleksandr Ianevski, Ziaurrehman Tanoli, Krister Wennerberg, Brinton Seashore-Ludlow, Olli Kallioniemi, Päivi Östling, Tero Aittokallio, Jani Saarela
Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data. Nucleic acids research (2023)
Moritz Otte, Johanna Stachelscheid, Markus Glaß, Linus Wahnschaffe, Qu Jiang, Waseem Lone, Aleksandr Ianevski, Tero Aittokallio, Javeed Iqbal, Michael Hallek, Stefan Hüttelmaier, Alexandra Schrader, Till Braun, Marco Herling
The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL. Cancers 15 (9) (2023)
Mona Meng Wang, Sarah E Coupland, Tero Aittokallio, Carlos R Figueiredo
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. British journal of cancer (2023)
Yingjia Chen, Liye He, Aleksandr Ianevski, Pilar Ayuda-Durán, Swapnil Potdar, Jani Saarela, Juho J Miettinen, Sari Kytölä, Susanna Miettinen, Mikko Manninen, Caroline A Heckman, Jorrit M Enserink, Krister Wennerberg, Tero Aittokallio
Robust scoring of selective drug responses for patient-tailored therapy selection. Nature protocols (2023)
Anni S Halkola, Kaisa Joki, Tuomas Mirtti, Marko M Mäkelä, Tero Aittokallio, Teemu Daniel Laajala
OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer. PLoS computational biology 19 (3) (2023)
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali, Stacey M Fernandes, Alberto J Arribas, Abdul K Hilli, Kjetil Taskén, Francesco Bertoni, Anthony R Mato, Emmanuel Normant, Jennifer R Brown, Geir Erland Tjønnfjord, Tero Aittokallio, Sigrid S Skånland
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (20) (2022)
Zhi Zhao, Manuela Zucknick, Tero Aittokallio
EnrichIntersect : an R package for custom set enrichment analysis and interactive visualization of intersecting sets. Bioinformatics advances 2 (1) (2022)
Aleksandr Ianevski, Anil K Giri, Tero Aittokallio
Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nature communications 13 (1) (2022)
Astrid Murumägi, Daniela Ungureanu, Suleiman Khan, Mariliina Arjama, Katja Välimäki, Aleksandr Ianevski, Philipp Ianevski, Rebecka Bergström, Alice Dini, Anna Kanerva, Riitta Koivisto-Korander, Johanna Tapper, Heini Lassus, Mikko Loukovaara, Andrus Mägi, Akira Hirasawa, Daisuke Aoki, Vilja Pietiäinen, Teijo Pellinen, Ralf Bützow, Tero Aittokallio, Olli Kallioniemi
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. British journal of cancer (2022)
Weikaixin Kong, Liye He, Jie Zhu, Oscar Brück, Kimmo Porkka, Caroline A Heckman, Sujie Zhu, Tero Aittokallio
An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia. Leukemia 36 (10) (2022)
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, Aleksandr Ianevski, Scott B Biering, Shuang Xu, Markus Hoffmann, Stefan H Pöhlmann, Michael Gale, Tero Aittokallio, Joshua T Schiffer, Judith M White, Stephen J Polyak
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiology spectrum 10 (5) (2022)
Zhi Zhao, Manuela Zucknick, Tero Aittokallio
EnrichIntersect : an R package for custom set enrichment analysis and interactive visualization of intersecting sets. Bioinformatics advances 2 (1) (2022)
Aleksandr Ianevski, Anil K Giri, Tero Aittokallio
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic acids research (2022)
Tero Aittokallio
What are the current challenges for machine learning in drug discovery and repurposing? Expert opinion on drug discovery 17 (5) (2022)
Liye He, Daria Bulanova, Jaana Oikkonen, Antti Häkkinen, Kaiyang Zhang, Shuyu Zheng, Wenyu Wang, Erdogan Pekcan Erkan, Olli Carpén, Titta Joutsiniemi, Sakari Hietanen, Johanna Hynninen, Kaisa Huhtinen, Sampsa Hautaniemi, Anna Vähärautio, Jing Tang, Krister Wennerberg, Tero Aittokallio
Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer. Briefings in bioinformatics 22 (6) (2022)
Yevhen Akimov, Daria Bulanova, Sanna Timonen, Krister Wennerberg, Tero Aittokallio
Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics. Molecular systems biology 16 (3) (2021)
Ziaurrehman Tanoli, Markus Vähä-Koskela, Tero Aittokallio
Artificial intelligence, machine learning, and drug repurposing in cancer. Expert opinion on drug discovery 16 (9) (2021)
Anna Cichońska, Balaguru Ravikumar, Robert J Allaway, Fangping Wan, Sungjoon Park, Oleksandr Isaev, Shuya Li, Michael Mason, Andrew Lamb, Ziaurrehman Tanoli, Minji Jeon, Sunkyu Kim, Mariya Popova, Stephen J Capuzzi, Jianyang Zeng, Kristen Dang, Gregory Koytiger, Jaewoo Kang, Carrow I Wells, Timothy M Willson, null null, Tudor I Oprea, Avner Schlessinger, David Harold Drewry, Gustavo Stolovitzky, Krister Wennerberg, Justin Guinney, Tero Aittokallio
Crowdsourced mapping of unexplored target space of kinase inhibitors. Nature communications 12 (1) (2021)
Farid Ahmad Siddiqui, Hanna Parkkola, Vladimir Vukić, Christina Oetken-Lindholm, Alok Jaiswal, Alexandros Kiriazis, Karolina Pavic, Tero Aittokallio, Tiina A Salminen, Daniel Kwaku Abankwa
Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling. Cancers 13 (4) (2021)
Aleksandr Ianevski, Jenni Lahtela, Komal K Javarappa, Philipp Sergeev, Bishwa R Ghimire, Prson Gautam, Markus Vähä-Koskela, Laura Turunen, Nora Linnavirta, Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Caroline A Heckman, Pirkko Mattila, Krister Wennerberg, Anil K Giri, Tero Aittokallio
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science advances 7 (8) (2021)
Krimo Toutah, Nabanita Nawar, Sanna Timonen, Helena Sorger, Yasir S Raouf, Shazreh Bukhari, Jana von Jan, Aleksandr Ianevski, Justyna M Gawel, Olasunkanmi O Olaoye, Mulu Geletu, Ayah Abdeldayem, Johan Israelian, Tudor B Radu, Abootaleb Sedighi, Muzaffar N Bhatti, Muhammad Murtaza Hassan, Pimyupa Manaswiyoungkul, Andrew E Shouksmith, Heidi A Neubauer, Elvin D de Araujo, Tero Aittokallio, Oliver H Krämer, Richard Moriggl, Satu Mustjoki, Marco Herling, Patrick Thomas Gunning
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of medicinal chemistry 64 (12) (2021)
Brian S White, Suleiman A Khan, Mike J Mason, Muhammad Ammad-Ud-Din, Swapnil Potdar, Disha Malani, Heikki Kuusanmäki, Brian J Druker, Caroline A Heckman, Olli Kallioniemi, Stephen E Kurtz, Kimmo Porkka, Cristina E Tognon, Jeffrey W Tyner, Tero Aittokallio, Krister Wennerberg, Justin Guinney
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. NPJ precision oncology 5 (1) (2021)
Judith M White, Joshua T Schiffer, Rachel A Bender Ignacio, Shuang Xu, Denis Kainov, Aleksandr Ianevski, Tero Aittokallio, Matthew B Friemann, Gene G Olinger, Stephen J Polyak
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 12 (6) (2021)
Disha Malani, Ashwini Kumar, Oscar Bruck, Mika Kontro, Bhagwan Yadav, Monica Hellesøy, Heikki Kuusanmaki, Olli Dufva, Matti Kankainen, Samuli Eldfors, Swapnil Potdar, Jani Saarela, Laura Turunen, Alun Parsons, Imre Vastrik, Katja Kivinen, Janna Saarela, Riikka Raty, Minna Lehto, Maija Wolf, Bjorn Tore Gjertsen, Mohamed El Missiry, Tero Aittokallio, Krister Wennerberg, Caroline A Heckman, Olli Kallioniemi, Kimmo Porkka
Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer discovery (2021)
Alok Jaiswal, Prson Gautam, Elina A Pietilä, Sanna Timonen, Nora Nordström, Yevhen Akimov, Nina Sipari, Ziaurrehman Tanoli, Thomas Fleischer, Kaisa Lehti, Krister Wennerberg, Tero Aittokallio
Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Molecular systems biology 17 (3) (2021)
S Pützer, L Varghese, J von Jan, T Braun, A K Giri, P Mayer, N Riet, S Timonen, S Oberbeck, H Kuusanmäki, Mohamed El Missiry, Marc-Henri Stern, Tero Aittokallio, S Newrzela, A Schrader, M Herling
Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine. Leukemia (2020)
Heli Julkunen, Anna Cichońska, Prson Gautam, Sandor Szedmak, Jane Douat, Tapio Pahikkala, Tero Aittokallio, Juho Rousu
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects. Nature communications 11 (1) (2020)
Xi Qiao, Ying Liu, Maria Llamazares Prada, Aravind K Mohan, Abhishekh Gupta, Alok Jaiswal, Mukund Sharma, Joni Merisaari, Heidi M Haikala, Kati Talvinen, Laxman Yetukuri, Joanna W Pylvänäinen, Juha Klefström, Pauliina Kronqvist, Annika Meinander, Tero Aittokallio, Ville Hietakangas, Martin Eilers, Jukka Westermarck
UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis. Cancer research 80 (7) (2020)
Shady Adnan-Awad, Olli Dufva, Aleksandr Ianevski, Bishwa R Ghimire, Jan Koski, Pilvi Maliniemi, Daniel Thomson, Andreas Schreiber, Caroline A Heckman, Perttu Koskenvesa, Matti Korhonen, Kimmo Porkka, Susan Branford, Tero Aittokallio, Matti Kankainen, Mohamed El Missiry
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia 35 (4) (2020)
Aleksandr Ianevski, Sanna Timonen, Alexander Kononov, Tero Aittokallio, Anil K Giri
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. PLoS computational biology 16 (2) (2020)
Otto I Pulkkinen, Prson Gautam, Ville Mustonen, Tero Aittokallio
Multiobjective optimization identifies cancer-selective combination therapies. PLoS computational biology 16 (12) (2020)
S Pützer, L Varghese, J von Jan, T Braun, A K Giri, P Mayer, N Riet, S Timonen, S Oberbeck, H Kuusanmäki, Mohamed El Missiry, Marc-Henri Stern, Tero Aittokallio, S Newrzela, A Schrader, M Herling
Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine. Leukemia 34 (9) (2020)
Alex H Wagner, Brian Walsh, Georgia Mayfield, David Tamborero, Dmitriy Sonkin, Kilannin Krysiak, Jordi Deu-Pons, Ryan P Duren, Jianjiong Gao, Julie McMurry, Sara Patterson, Catherine Del Vecchio Fitz, Beth A Pitel, Ozman U Sezerman, Kyle Ellrott, Jeremy L Warner, Damian T Rieke, Tero Aittokallio, Ethan Cerami, Deborah I Ritter, Lynn M Schriml, Robert R Freimuth, Melissa A Haendel, Gordana Raca, Subha Madhavan, Michael Baudis, Jacques S Beckmann, Rodrigo Dienstmann, Debyani Chakravarty, Xuan Shirley Li, Susan Mockus, Olivier Elemento, Nikolaus Schultz, Nuria Lopez-Bigas, Mark Lawler, Jeremy Goecks, Malachi Griffith, Malachi Griffith, Adam A Margolin, null null
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nature genetics 52 (4) (2020)
Abhishekh Gupta, Prson Gautam, Krister Wennerberg, Tero Aittokallio
A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Communications biology 3 (1) (2020)
Michael Gabriel, Vidal Fey, Taija Heinosalo, Prem Adhikari, Kalle Rytkönen, Tuomo Komulainen, Kaisa Huhtinen, Teemu Daniel Laajala, Harri Siitari, Arho Virkki, Pia Suvitie, Harry Kujari, Tero Aittokallio, Antti Perheentupa, Matti Poutanen
A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions. Scientific data 7 (1) (2020)
Jing Tang, Prson Gautam, Abhishekh Gupta, Liye He, Sanna Timonen, Yevhen Akimov, Wenyu Wang, Agnieszka Szwajda, Alok Jaiswal, Denes Turei, Bhagwan Yadav, Matti Kankainen, Jani Saarela, Julio Saez-Rodriguez, Krister Wennerberg, Tero Aittokallio
Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. NPJ systems biology and applications 5 (2019)
Heidi M Haikala, Johanna M Anttila, Elsa Marques, Tiina Raatikainen, Mette Ilander, Henna Hakanen, Hanna Ala-Hongisto, Mariel Savelius, Diego Balboa, Björn von Eyss, Vilja Eskelinen, Pauliina Munne, Anni I Nieminen, Timo Otonkoski, Julia Schüler, Teemu D Laajala, Tero Aittokallio, Harri Jaakko Sihto, Johanna Mattson, Päivi Heikkilä, Marjut Leidenius, Heikki Joensuu, Mohamed El Missiry, Panu Kovanen, Martin Eilers, Joel D Leverson, Juha Klefström
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nature communications 10 (1) (2019)
Heidi M Haikala, Johanna M Anttila, Elsa Marques, Tiina Raatikainen, Mette Ilander, Henna Hakanen, Hanna Ala-Hongisto, Mariel Savelius, Diego Balboa, Björn von Eyss, Vilja Eskelinen, Pauliina Munne, Anni I Nieminen, Timo Otonkoski, Julia Schüler, Teemu D Laajala, Tero Aittokallio, Harri Jaakko Sihto, Johanna Mattson, Päivi Heikkilä, Marjut Leidenius, Heikki Joensuu, Mohamed El Missiry, Panu Kovanen, Martin Eilers, Joel D Leverson, Juha Klefström
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nature communications 10 (1) (2019)
Otto Kauko, Caitlin M O'Connor, Evgeny Kulesskiy, Jaya Sangodkar, Anna Aakula, Sudeh Izadmehr, Laxman Yetukuri, Bhagwan Yadav, Artur Padzik, Teemu Daniel Laajala, Pekka Haapaniemi, Majid Momeny, Taru Varila, Michael Ohlmeyer, Tero Aittokallio, Krister Wennerberg, Goutham Narla, Jukka Westermarck
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science translational medicine 10 (450) (2019)
Anil K Giri, Aleksandr Ianevski, Tero Aittokallio
Genome-wide off-targets of drugs: risks and opportunities. Cell biology and toxicology 35 (6) (2019)
Tero Aittokallio, Andreas Scherer, Matti Poutanen, Leonard P Freedman
Matched preclinical designs for improved translatability. Science translational medicine 9 (389) (2018)
Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E Kovanen, Teija Ojala, Dean A Lee, Thomas P Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young-Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C Chan, Koichi Ohshima, Fumihiro Ishida, Mohamed El Missiry
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nature communications 9 (1) (2018)
Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Jaakko Sihto, Reidar Grénman, Stina M Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni
Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular cancer therapeutics 17 (9) (2018)
Oscar Brück, Sami Blom, Olli Dufva, Riku Turkki, Himanshu Chheda, Antonio Ribeiro, Panu Kovanen, Tero Aittokallio, Perttu Koskenvesa, Olli Kallioniemi, Kimmo Porkka, Teijo Pellinen, Satu Mustjoki
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 32 (7) (2018)
Daria Bulanova, Aleksandr Ianevski, Andrii Bugai, Yevhen Akimov, Suvi Kuivanen, Henrik Paavilainen, Laura Kakkola, Jatin Nandania, Laura Turunen, Tiina Ohman, Hanna Ala-Hongisto, Hanna M Pesonen, Marika S Kuisma, Anni Honkimaa, Emma L Walton, Valentyn Oksenych, Martina B Lorey, Dmitry Guschin, Jungmin Shim, Jinhee Kim, Thoa T Than, So Young Chang, Veijo Hukkanen, Evgeny Kulesskiy, Varpu S Marjomaki, Ilkka Julkunen, Tuula Anneli Nyman, Sampsa Matikainen, Jani S Saarela, Famara Sane, Didier Hober, Gülsah Gabriel, Jef K De Brabander, Miika Martikainen, Marc P Windisch, Ji-Young Min, Roberto Bruzzone, Tero Aittokallio, Markus Vähä-Koskela, Olli Vapalahti, Arto Pulk, Vidya Velagapudi, Denis E Kainov
Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses 9 (10) (2017)
Anna Cichońska, Balaguru Ravikumar, Elina Parri, Sanna Timonen, Tapio Pahikkala, Antti Airola, Krister Wennerberg, Juho Rousu, Tero Aittokallio
Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors. PLoS computational biology 13 (8) (2017)
Balaguru Ravikumar, Tero Aittokallio
Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert opinion on drug discovery 13 (2) (2017)

Tero Aittokallio.css-eqlu8i{font-size:small;padding-left:4px;} (T Aittokallio)

Publication Activity (10 Years)

Top Topics

Top Venues

Tero Aittokallio (T Aittokallio)